Below are the most recent publications written about "HIV Reverse Transcriptase" by people in Profiles.
-
Parkin NT, Avila-Rios S, Bibby DF, Brumme CJ, Eshleman SH, Harrigan PR, Howison M, Hunt G, Ji H, Kantor R, Ledwaba J, Lee ER, Mat?as-Florentino M, Mbisa JL, Noguera-Julian M, Paredes R, Rivera-Amill V, Swanstrom R, Zaccaro DJ, Zhang Y, Zhou S, Jennings C. Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping. Viruses. 2020 06 27; 12(7).
-
SahBandar IN, Samonte G, Telan E, Siripong N, Belcaid M, Schanzenbach D, Leano S, Chagan-Yasutan H, Hattori T, Shikuma CM, Ndhlovu LC. Ultra-Deep Sequencing Analysis on HIV Drug-Resistance-Associated Mutations Among HIV-Infected Individuals: First Report from the Philippines. AIDS Res Hum Retroviruses. 2017 Nov; 33(11):1099-1106.
-
Kumari N, Kulkarni AA, Lin X, McLean C, Ammosova T, Ivanov A, Hipolito M, Nekhai S, Nwulia E. Inhibition of HIV-1 by curcumin A, a novel curcumin analog. Drug Des Devel Ther. 2015; 9:5051-60.
-
L?pez P, Rivera-Amill V, Paulino-Ramirez R, Yamamura Y. Short Communication: HIV-1 Subtype B in the Dominican Republic: Evolution and Molecular Epidemiology. AIDS Res Hum Retroviruses. 2015 Jul; 31(7):679-84.
-
Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011 Jul 16; 378(9787):229-37.
-
Van Duyne R, Guendel I, Narayanan A, Gregg E, Shafagati N, Tyagi M, Easley R, Klase Z, Nekhai S, Kehn-Hall K, Kashanchi F. Varying modulation of HIV-1 LTR activity by Baf complexes. J Mol Biol. 2011 Aug 19; 411(3):581-96.
-
Dash C, Ahmadibeni Y, Hanley MJ, Pandhare J, Gotte M, Le Grice SF, Parang K. Inhibition of multi-drug resistant HIV-1 reverse transcriptase by nucleoside ?-triphosphates. Bioorg Med Chem Lett. 2011 Jun 15; 21(12):3519-22.
-
Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 2010 Mar; 201(5):662-71.
-
Dash C, Scarth BJ, Badorrek C, G?tte M, Le Grice SF. Examining the ribonuclease H primer grip of HIV-1 reverse transcriptase by charge neutralization of RNA/DNA hybrids. Nucleic Acids Res. 2008 Nov; 36(20):6363-71.
-
Ehteshami M, Scarth BJ, Tchesnokov EP, Dash C, Le Grice SF, Hallenberger S, Jochmans D, G?tte M. Mutations M184V and Y115F in HIV-1 reverse transcriptase discriminate against "nucleotide-competing reverse transcriptase inhibitors". J Biol Chem. 2008 Oct 31; 283(44):29904-11.